1. Home
  2. PUBM vs IMRX Comparison

PUBM vs IMRX Comparison

Compare PUBM & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$8.64

Market Cap

416.8M

Sector

Technology

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$6.60

Market Cap

366.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
IMRX
Founded
2006
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.8M
366.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PUBM
IMRX
Price
$8.64
$6.60
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$18.45
$17.20
AVG Volume (30 Days)
503.9K
1.3M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$288,382,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.01
$1.10
52 Week High
$17.32
$10.08

Technical Indicators

Market Signals
Indicator
PUBM
IMRX
Relative Strength Index (RSI) 43.81 53.99
Support Level $8.83 $6.49
Resistance Level $9.13 $6.98
Average True Range (ATR) 0.30 0.41
MACD -0.04 0.09
Stochastic Oscillator 20.79 77.78

Price Performance

Historical Comparison
PUBM
IMRX

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: